This retrospective study was designed to assess the efficacy and safety of ICIs combined with single-drug chemotherapy without platinum in patients with EGFR-TKI-resistant advanced NSCLC in a real-world setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.